- Home
- CSIQ vs PRAX Comparison
CSIQ vs PRAX Comparison
Compare CSIQ & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSIQ
- PRAX
- Stock Information
- Founded
- CSIQ 2001
- PRAX 2015
- Country
- CSIQ Canada
- PRAX United States
- Employees
- CSIQ N/A
- PRAX N/A
- Industry
- CSIQ Semiconductors
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- CSIQ Technology
- PRAX Health Care
- Exchange
- CSIQ Nasdaq
- PRAX Nasdaq
- Market Cap
- CSIQ 715.3M
- PRAX 599.7M
- IPO Year
- CSIQ 2006
- PRAX 2020
- Fundamental
- Price
- CSIQ $11.24
- PRAX $44.56
- Analyst Decision
- CSIQ Hold
- PRAX Strong Buy
- Analyst Count
- CSIQ 11
- PRAX 11
- Target Price
- CSIQ $16.49
- PRAX $114.73
- AVG Volume (30 Days)
- CSIQ 1.4M
- PRAX 302.6K
- Earning Date
- CSIQ 05-15-2025
- PRAX 05-02-2025
- Dividend Yield
- CSIQ N/A
- PRAX N/A
- EPS Growth
- CSIQ N/A
- PRAX N/A
- EPS
- CSIQ N/A
- PRAX N/A
- Revenue
- CSIQ $5,860,923,000.00
- PRAX $8,122,000.00
- Revenue This Year
- CSIQ $24.47
- PRAX N/A
- Revenue Next Year
- CSIQ $17.17
- PRAX N/A
- P/E Ratio
- CSIQ N/A
- PRAX N/A
- Revenue Growth
- CSIQ N/A
- PRAX 270.02
- 52 Week Low
- CSIQ $6.57
- PRAX $26.70
- 52 Week High
- CSIQ $19.55
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- CSIQ 62.22
- PRAX 69.68
- Support Level
- CSIQ $9.53
- PRAX $40.57
- Resistance Level
- CSIQ $10.65
- PRAX $38.90
- Average True Range (ATR)
- CSIQ 0.60
- PRAX 2.60
- MACD
- CSIQ 0.05
- PRAX 0.66
- Stochastic Oscillator
- CSIQ 86.36
- PRAX 87.55
About CSIQ Canadian Solar Inc. (ON)
Canadian Solar Inc is a Canadian solar technology and renewable energy company. It is a manufacturer of solar photovoltaic modules, a provider of battery energy storage solutions, and a developer of utility-scale solar power and battery energy storage projects.. It operates through two business segments CSI Solar and Recurrent Energy segment. The CSI Solar segment focused on solar modules and battery energy storage manufacturing and products. Its Recurrent segment focused on utility-scale solar power and battery energy storage project development and operation. Key revenue is generated from CSI Solar segment.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.